ATE273954T1 - Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen - Google Patents

Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen

Info

Publication number
ATE273954T1
ATE273954T1 AT99964583T AT99964583T ATE273954T1 AT E273954 T1 ATE273954 T1 AT E273954T1 AT 99964583 T AT99964583 T AT 99964583T AT 99964583 T AT99964583 T AT 99964583T AT E273954 T1 ATE273954 T1 AT E273954T1
Authority
AT
Austria
Prior art keywords
compounds
treatment
inflammatory diseases
inflammatory
diseases
Prior art date
Application number
AT99964583T
Other languages
German (de)
English (en)
Inventor
Duncan Robert Armour
David Brown
Miles S Congreave
Paul Martin Gore
Darren Victor Steven Green
Stuart Holman
Torquil Iain Maclean Jack
Steven Philip Keeling
Andrew Mcmurtrie Mason
Karen Morriss
Nigel Grahame Ramsden
Peter Ward
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE273954T1 publication Critical patent/ATE273954T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99964583T 1998-12-18 1999-12-16 Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen ATE273954T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828074.6A GB9828074D0 (en) 1998-12-18 1998-12-18 Therapeutically useful compounds
PCT/EP1999/010000 WO2000037444A1 (en) 1998-12-18 1999-12-16 Compounds useful in the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE273954T1 true ATE273954T1 (de) 2004-09-15

Family

ID=10844608

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99964583T ATE273954T1 (de) 1998-12-18 1999-12-16 Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen

Country Status (26)

Country Link
US (1) US6867192B1 (enExample)
EP (1) EP1140837B1 (enExample)
JP (1) JP4431282B2 (enExample)
KR (1) KR20010101258A (enExample)
CN (1) CN1330637A (enExample)
AR (1) AR023727A1 (enExample)
AT (1) ATE273954T1 (enExample)
AU (1) AU760169B2 (enExample)
BR (1) BR9916282A (enExample)
CA (1) CA2355630A1 (enExample)
CO (1) CO5170533A1 (enExample)
CZ (1) CZ20012209A3 (enExample)
DE (1) DE69919580T2 (enExample)
ES (1) ES2226488T3 (enExample)
GB (1) GB9828074D0 (enExample)
GT (1) GT199900217A (enExample)
HK (1) HK1038744A1 (enExample)
HU (1) HUP0104867A3 (enExample)
IL (1) IL142908A0 (enExample)
NO (1) NO20012995L (enExample)
NZ (1) NZ511478A (enExample)
PE (1) PE20001387A1 (enExample)
PL (1) PL348059A1 (enExample)
TR (1) TR200101709T2 (enExample)
WO (1) WO2000037444A1 (enExample)
ZA (1) ZA200103948B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051487A1 (en) 1999-12-28 2001-07-19 Pfizer Products Inc. Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
GB0014881D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014947D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014851D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0014849D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB0014883D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
GB0127423D0 (en) * 2001-11-15 2002-01-09 Glaxo Group Ltd Process
GB0218630D0 (en) 2002-08-10 2002-09-18 Tanabe Seiyaku Co Novel compounds
WO2004103967A2 (en) 2003-05-20 2004-12-02 Genentech, Inc. Thiocarbamate inhibitors of alpha-4 integrins
KR20070029733A (ko) 2004-06-04 2007-03-14 제넨테크, 인크. 다발성 경화증의 치료 방법
US8310442B2 (en) 2005-02-23 2012-11-13 Pixtronix, Inc. Circuits for controlling display apparatus
US9261694B2 (en) 2005-02-23 2016-02-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US7999994B2 (en) 2005-02-23 2011-08-16 Pixtronix, Inc. Display apparatus and methods for manufacture thereof
US8159428B2 (en) 2005-02-23 2012-04-17 Pixtronix, Inc. Display methods and apparatus
US20070205969A1 (en) 2005-02-23 2007-09-06 Pixtronix, Incorporated Direct-view MEMS display devices and methods for generating images thereon
US9158106B2 (en) 2005-02-23 2015-10-13 Pixtronix, Inc. Display methods and apparatus
US8519945B2 (en) 2006-01-06 2013-08-27 Pixtronix, Inc. Circuits for controlling display apparatus
US9229222B2 (en) 2005-02-23 2016-01-05 Pixtronix, Inc. Alignment methods in fluid-filled MEMS displays
US8482496B2 (en) 2006-01-06 2013-07-09 Pixtronix, Inc. Circuits for controlling MEMS display apparatus on a transparent substrate
US7742016B2 (en) 2005-02-23 2010-06-22 Pixtronix, Incorporated Display methods and apparatus
US9082353B2 (en) 2010-01-05 2015-07-14 Pixtronix, Inc. Circuits for controlling display apparatus
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US8526096B2 (en) 2006-02-23 2013-09-03 Pixtronix, Inc. Mechanical light modulators with stressed beams
US9176318B2 (en) * 2007-05-18 2015-11-03 Pixtronix, Inc. Methods for manufacturing fluid-filled MEMS displays
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
US8169679B2 (en) 2008-10-27 2012-05-01 Pixtronix, Inc. MEMS anchors
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR101659642B1 (ko) 2010-02-02 2016-09-26 픽스트로닉스 인코포레이티드 디스플레이 장치를 제어하기 위한 회로
WO2011097252A2 (en) 2010-02-02 2011-08-11 Pixtronix, Inc. Methods for manufacturing cold seal fluid-filled display apparatus
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
AR091305A1 (es) 2012-01-31 2015-01-28 Genentech Inc ANTICUERPOS ANTI-IgE Y SUS METODOS DE USO
US9134552B2 (en) 2013-03-13 2015-09-15 Pixtronix, Inc. Display apparatus with narrow gap electrostatic actuators
WO2015181837A2 (en) * 2014-05-30 2015-12-03 Sphaera Pharma Pvt. Ltd. Novel compounds as anti-tubercular agents
PL3319639T3 (pl) * 2015-07-08 2021-03-08 Axerovision, Inc. Kompozycje farmaceutyczne zawierające antagonistę integryny alfa4 do stosowania w leczeniu stanów zapalnych oka
HRP20250052T1 (hr) 2015-10-06 2025-03-14 F. Hoffmann - La Roche Ag Postupak liječenja multiple skleroze
HRP20220479T1 (hr) * 2016-06-01 2022-05-27 Athira Pharma, Inc. Spojevi
CN109722455B (zh) * 2017-10-31 2022-03-11 中国科学院天津工业生物技术研究所 微生物发酵生产谷内酯的方法、工程菌及应用
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
CN112969687B (zh) 2018-10-30 2024-08-23 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
CN114222730B (zh) 2019-08-14 2024-09-10 吉利德科学公司 用于抑制α4β7整合素的化合物
JP2023546915A (ja) * 2020-10-21 2023-11-08 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593858A1 (de) 1967-03-02 1970-10-29 Hoechst Ag Verfahren zur Herstellung tyrosinhaltiger Peptide und deren Derivaten
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
AU728435B2 (en) 1997-05-29 2001-01-11 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
ES2257808T3 (es) 1997-05-29 2006-08-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Acidos biarilalcanoicos como inhibidores de adhesion celular.
CA2291778A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
ATE256699T1 (de) * 1997-05-30 2004-01-15 Celltech Therapeutics Ltd Entzündungshemmende tyrosin-derivate

Also Published As

Publication number Publication date
HUP0104867A3 (en) 2002-06-28
US6867192B1 (en) 2005-03-15
ES2226488T3 (es) 2005-03-16
PL348059A1 (en) 2002-05-06
CZ20012209A3 (cs) 2001-09-12
GT199900217A (es) 2001-06-09
HUP0104867A2 (hu) 2002-04-29
GB9828074D0 (en) 1999-02-17
NO20012995D0 (no) 2001-06-15
PE20001387A1 (es) 2000-12-22
EP1140837B1 (en) 2004-08-18
BR9916282A (pt) 2001-10-02
JP4431282B2 (ja) 2010-03-10
CA2355630A1 (en) 2000-06-29
AR023727A1 (es) 2002-09-04
IL142908A0 (en) 2002-04-21
AU3039100A (en) 2000-07-12
EP1140837A1 (en) 2001-10-10
WO2000037444A1 (en) 2000-06-29
CO5170533A1 (es) 2002-06-27
NO20012995L (no) 2001-08-15
TR200101709T2 (tr) 2001-12-21
JP2002533326A (ja) 2002-10-08
HK1038744A1 (zh) 2002-03-28
AU760169B2 (en) 2003-05-08
CN1330637A (zh) 2002-01-09
ZA200103948B (en) 2002-11-15
NZ511478A (en) 2003-08-29
DE69919580T2 (de) 2005-09-01
DE69919580D1 (de) 2004-09-23
KR20010101258A (ko) 2001-11-14

Similar Documents

Publication Publication Date Title
ATE273954T1 (de) Verbindungen zur anwendung bei der behandlung entzündlicher erkrankungen
DE69509544D1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE246500T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE60124576D1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60138129D1 (de) Apparat zur behandlung von zähnen
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE262331T1 (de) Heterocyclische vinylether zur behandlung neurologischer krankheiten
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE60028358D1 (de) Hmg1 antagonisten zur behandlung von entzündungen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE424837T1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE69914951D1 (de) Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen
DE69905214D1 (de) Mittel zur Behandlung der Osteoporose
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties